 |
|
Regular use of selective COX-2 inhibitors decreases risk of breast cancer
January 30, 2006Regular use of selective COX-2 inhibitors significantly reduces the risk of breast cancer. A case-control study published today in the open access journal BMC Cancer observed that daily use of selective COX-2 inhibitors, including celecoxib (Celebrex) and rofecoxib (Vioxx), was associated with a 71% reduction in the risk of breast cancer. Non-selective COX-2 inhibitors, such as aspirin and ibuprofen, also reduced the risk of breast cancer. This study highlights the potential of nonsteroidal anti-inflammatory drugs (NSAIDs) for the prevention of breast cancer.
Randall Harris and colleagues from The Ohio State University College of Medicine and Public Health, Columbus, Ohio, USA, collected data on 323 patients with invasive breast cancer shortly after their diagnosis. Harris et al. matched the patients for age, race and county of residence with 649 control individuals with no personal history of cancer. Data collected for patients and controls included information on breast cancer risk factors, and the use of selective COX-2 inhibitors and other NSAIDs.
Harris et al.'s results show that selective COX-2 inhibitors, as a group, were associated with a significantly reduced risk of breast cancer (OR=0.29) when taken daily for at least two years: a daily dose of 200 mg celecoxib reduced the risk of breast cancer by 83% and a daily dose of 25 mg rofecoxib reduced the risk of breast cancer by 64%. Regular use of non-selective COX-2 inhibitors-aspirin (325 mg), ibuprofen (200mg) and naproxen (250 mg)-also significantly reduced the risk of breast cancer, but less so than regular intake of selective COX-2 inhibitors. Ibuprofen and aspirin significantly decreased the risk of developing breast cancer when taken at least every other day for at least five years. Regular intake of acetaminophen, an analgesic lacking COX-2 activity, had no effect on the risk of breast cancer.
BioMed Central
BioMed Central
COX-2 Inhibitors Current Events and COX-2 Inhibitors News RSSIs short-term Celecoxib intervention a effective method for preventing gastric carcinogenesis?
Since the isolation and culture of Helicobacter pylori (H. pylori) in 1983, this bacterium has become accepted as an important human pathogen for the development of gastritis, peptic ulcer, and gastric cancer.
Sensitizing tumor response to cancer therapy
Two forms of skin and brain cancer respond very poorly to chemotherapy and radiation: melanoma and glioblastoma multiforme brain cancer.
Potential Lung Disease Biomarkers Yield Clues to COX-2 Inhibitor Side Effects
In searching for a simple way to identify individuals with smoking-related lung injury, scientists at Weill Cornell Medical College have stumbled upon a potential explanation for why the class of pain-relievers known as COX-2 inhibitors increases the risk of heart problems among users.
USC researchers develop new drug to target tumor cells and blood vessels
Researchers at the University of Southern California have identified a new drug compound that appears to target tumor cells and surrounding blood vessels without the negative side effects typically associated with Cox-2 inhibitors.
Licorice compound offers new cancer prevention strategy
A chemical component of licorice may offer a new approach to preventing colorectal cancer without the adverse side effects of other preventive therapies, Vanderbilt University Medical Center researchers report.
Brain study may lead to improved epilepsy treatments
Using a rodent model of epilepsy, researchers found one of the body's own neurotransmitters released during seizures, glutamate, turns on a signaling pathway in the brain that increases production of a protein that could reduce medication entry into the brain.
Popular Arthritis Drug May Disrupt Heart Rhythm, UB Research Finds
Celebrex, a popular arthritis drug that blocks pain by inhibiting an enzyme known as COX-2, has been shown in laboratory studies to induce arrhythmia, or irregular beating of the heart, via a novel pathway unrelated to its COX-2 inhibition.
New study may explain Vioxx side effects
Vioxx and related pain medications were taken off the market in 2004 because they caused dangerous heart problems in some people.
COX-2 inhibitors delay pancreatic cancer precursors in mice
Nimesulide, a cyclooxygenase-2 (COX-2) inhibitor, delays the progression of precancerous pancreatic lesions in mice, according to researchers at David Geffen School of Medicine at UCLA.
Experimental gene therapy 'abolishes' arthritis pain and lessens joint damage
Early-stage research has found that a new gene therapy can nearly eliminate arthritis pain, and significantly reduce long-term damage to the affected joints, according to a study published today in the journal Arthritis and Rheumatism.
More COX-2 Inhibitors Current Events and COX-2 Inhibitors News Articles
 |
Dollar Store Dr. Bob and the Cox-2 Inhibitors (Primary Contributor) |
|
COX-2 inhibitors intensify aspirin's gastric effects: even at low doses. (Gastroenterology).: An article from: Internal Medicine News by Robert Finn (Author) This digital document is an article from Internal Medicine News, published by International Medical News Group on April 1, 2003. The length of the article is 374 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: COX-2 inhibitors intensify aspirin's gastric effects: even at low doses. (Gastroenterology). Author: Robert Finn Publication: Internal Medicine News (Magazine/Journal) Date: April 1, 2003 Publisher: International Medical News Group Volume: 36 Issue: 7 Page: 55(1) Distributed by Thomson... | |
 |
Inflama-Rest COX-2 Inhibitor 90 tabs by SOURCE NATURALS Inflama-Rest is a Bio-Aligned formula that may ease joint function and support comfortable movement via inhibition of the COX-2 enzyme. It also addresses additional factors shown in scientific research to influence muscle and joint comfort: nuclear factor-kappa B activity, leukotriene regulation and nitric oxide production. Inflama-Rest helps to protect cells from free radical damage. It is specially formulated with adaptogenic herbs and minerals that may help reduce muscle tension associated with physical and emotional stress. * Picture may be of different size or flavor |
 |
Source Naturals Inflama-Rest, Tablets, 90 tablets by Source Naturals Dietary supplement. Cox-2 Inhibitor. Bio-Align. Inflama-Rest is a Bio-Aligned formula that may ease joint function and supports comfortable movement via inhibition of the COX-2 enzyme. It also addresses additional factors shown in scientific research to influence muscle and joint comfort: nuclear factor-kappa B activity, cytokine inhibition and nitric oxide production. Inflama-Rest helps protect cells from free radical damage and is specially formulated with adaptogenic herbs and specific minerals that may help reduce muscle tension associated with physical and emotional stress (These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease). Contains no yeast, dairy, egg, gluten or wheat. Contains... |
|
Small Talk by Dr. Bob & the Cox-2 Inhibitors | |
|
|
Rolling Stone Dr. Bob and the Cox-2 Inhibitors (Primary Contributor) |
 |
Trends in Cox-2 Inhibitor Research by Maynard J. Howardell (Editor) Cox-2 Inhibitors are newly developed drugs for inflammation that selectively block the Cox-2 enzyme. Blocking this enzyme impedes the production of the chemical messengers (prostaglandins) that cause the pain and swelling of arthritis inflammation. Cox-2 inhibitors are a new class of non-steroidal anti-inflammatory drugs (NSAIDS). Because they selectively block the Cox-2 enzyme and not the Cox-1 enzyme, these drugs are uniquely different from traditional NSAIDS. This book explores new research in the field. |
 |
Green Blues Dr. Bob and the Cox-2 Inhibitors (Primary Contributor) |
|
COX-2 Inhibitors Are 'Safer Aspirins,' Not 'Superaspirins'.(Brief Article): An article from: Family Practice News by Bruce Jancin (Author) This digital document is an article from Family Practice News, published by International Medical News Group on April 1, 2000. The length of the article is 1540 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: COX-2 Inhibitors Are 'Safer Aspirins,' Not 'Superaspirins'.(Brief Article) Author: Bruce Jancin Publication: Family Practice News (Magazine/Journal) Date: April 1, 2000 Publisher: International Medical News Group Volume: 30 Issue: 7 Page: 32 Article Type: Brief Article, Product/Service Evaluation Distributed by Thomson... | |
|
|
Friendly Dr. Bob and the Cox-2 Inhibitors (Primary Contributor) |
| © 2009 BrightSurf.com |